Inhibitory effects and mechanisms of the anti-covid-19 traditional Chinese prescription, Keguan-1, on acute lung injury.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE:

Keguan-1, a new traditional Chinese medicine (TCM) prescription contained seven Chinese herbs, is developed to treat coronavirus disease 19 (COVID-19). The first internationally registered COVID-19 randomised clinical trial on integrated therapy demonstrated that Keguan-1 significantly reduced the incidence of ARDS and inhibited the severe progression of COVID-19.

AIM OF THE STUDY:

To investigate the protective mechanism of Keguan-1 on ARDS, a lipopolysaccharide (LPS)-induced acute lung injury (ALI) model was used to simulate the pathological state of ARDS in patients with COVID-19, focusing on its effect and mechanism on ALI.

MATERIALS AND METHODS:

Mice were challenged with LPS (2 mg/kg) by intratracheal instillation (i.t.) and were orally administered Keguan-1 (low dose, 1.25 g/kg; medium dose, 2.5 g/kg; high dose, 5 g/kg) after 2 h. Bronchoalveolar lavage fluid (BALF) and lung tissue were collected 6 h and 24 h after i.t. administration of LPS. The levels of inflammatory factors tumour necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-1β, keratinocyte-derived chemokine (KC or mCXCL1), macrophage inflammatory protein 2 (MIP2 or mCXCL2), angiotensin II (Ang II), and endothelial cell junction-associated proteins were analysed using ELISA or western blotting.

RESULTS:

Keguan-1 improved the survival rate, respiratory condition, and pathological lung injury; decreased the production of proinflammatory factors (TNF-α, IL-6, IL-1β, KC, and MIP2) in BALF and the number of neutrophils in the lung tissues; and ameliorated inflammatory injury in the lung tissues of the mice with LPS-induced ALI. Keguan-1 also reduced the expression of Ang II and the adhesion molecule ICAM-1; increased tight junction proteins (JAM-1 and claudin-5) and VE-cadherin expression; and alleviated pulmonary vascular endothelial injury in LPS-induced ALI.

CONCLUSION:

These results demonstrate that Keguan-1 can improve LPS-induced ALI by reducing inflammation and pulmonary vascular endothelial injury, providing scientific support for the clinical treatment of patients with COVID-19. Moreover, it also provides a theoretical basis and technical support for the scientific use of TCMs in emerging infectious diseases.

• Authors: Zhaofang Bai, Pengyan Li, Jincai Wen, Yanzhong Han, Yuanyuan Cui, Yongfeng Zhou, Zhuo Shi, Shuaishuai Chen, Qiang Li, Xu Zhao, Zhongxia Wang, Ruisheng Li, Yuming Guo, Xiaoyan Zhan, Guang Xu, Kaixin Ding, Jiabo Wang, Xiaohe Xiao
• Journal: Journal of ethnopharmacology (J Ethnopharmacol) Vol. 285 Pg. 114838 (Mar 01 2022) ISSN: 1872-7573 [Electronic] Ireland
• PMID: 34788645 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• Antiviral Agents
• Capsules
• Chemokine CXCL2
• Cxcl2 protein, mouse
• Drugs, Chinese Herbal
• Interleukin-1beta
• Interleukin-6
• Peptide Fragments
• Tumor Necrosis Factor-alpha
• yinqiao
• interleukin-1beta (163-171)

Topics

• Acute Lung Injury (drug therapy, immunology, pathology)
• Animals
• Antiviral Agents (pharmacology)
• Bronchoalveolar Lavage Fluid (immunology, virology)
• COVID-19 (complications, immunology, virology)
• Capsules
• Chemokine CXCL2 (analysis)
• Coix
• Drugs, Chinese Herbal (pharmacology)
• Forsythia
• Interleukin-1beta (analysis)
• Interleukin-6 (analysis)
• Lonicera
• Lung (drug effects, metabolism, pathology, virology)
• Mice
• Mortality
• Morus
• Peptide Fragments (analysis)
• Prunus armeniaca
• Respiration (drug effects)
• SARS-CoV-2
• Treatment Outcome
• Tumor Necrosis Factor-alpha (analysis)